Article
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
Cancer cell - 1 Jul 2007
Li Danan, Shimamura Takeshi, Ji Hongbin, Chen Liang, Haringsma Henry J, McNamara Kate, Liang Mei-Chih, Perera Samanthi A, Zaghlul Sara, Borgman Christa L, Kubo Shigeto, Takahashi Masaya, Sun Yanping, Chirieac Lucian R, Padera Robert F, Lindeman Neal I, Jänne Pasi A, Thomas Roman K, Meyerson Matthew L, Eck Michael J, Engelman Jeffrey A, Shapiro Geoffrey I, Wong Kwok-Kin
Abstract excerpt
The EGFR T790M mutation has been identified in tumors from lung cancer patients that eventually develop resistance to erlotinib. In this study, we generated a mouse model with doxycycline-inducible expression of a mutant EGFR containing both L858R, an erlotinib-sensitizing mutation, and the T790M resistance mutation (EGFR TL). Expression of EGFR TL led to development of peripheral adenocarcinomas with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
